0
0

Chapter 28. Clozapine

Stephen R. Marder, M.D.; Donna A. Wirshing, M.D.
DOI: 10.1176/appi.books.9781585623860.413523

Sections

Excerpt

Clozapine has played a critical role in the history of therapeutics for psychosis. When clozapine was initially developed in the 1960s (following its synthesis in 1958 in Switzerland), there was skepticism as to whether an agent that barely caused catalepsy in rodents could be an effective antipsychotic. According to Hippius (1999), there was limited enthusiasm for this drug because it was inconsistent with the "neuroleptic dogma" that extrapyramidal side effects (EPS) were an essential feature of an antipsychotic agent. Nevertheless, Hippius and others challenged this dogma and supported clozapine's development in Germany. As a result, clozapine was eventually marketed in a number of countries in Europe.

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

FIGURE 28–1. Chemical structure of clozapine.

References

Allison DB, Mentore JL, Heo M, et al: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686–1696, 1999
[PubMed]
 
Alvir JM, Lieberman JA, Safferman AZ, et al: Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 329:162–167, 1993
[PubMed]
 
American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596–601, 2004
 
Ames D, Wirshing WC, Baker RW, et al: Predictive value of eosinophilia for neutropenia during clozapine treatment. J Clin Psychiatry 57:579–581, 1996
[PubMed]
 
Amsler HA, Teerenhovi L, Barth E, et al: Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic. Acta Psychiatr Scand 56:241–488, 1977
[PubMed]
 
Anderson ES, Powers PS: Neuroleptic malignant syndrome associated with clozapine use. J Clin Psychiatry 52:102–104, 1991
[PubMed]
 
Andersson B, Marin P, Lissner L, et al: Testosterone concentrations in women and men with NIDDM. Diabetes Care 17:405–411, 1994
[PubMed]
 
Angermeyer MC, Loffler W, Muller P, et al: Patients' and relatives' assessment of clozapine treatment. Psychol Med 31:509–517, 2001
[PubMed]
 
Azorin JM, Spiegel R, Remington G, et al: A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 158:1305–1313, 2001
[PubMed]
 
Barbini B, Scherillo P, Benedetti F, et al: Response to clozapine in acute mania is more rapid than that of chlorpromazine. Int Clin Psychopharmacol 12:109–112, 1997
[PubMed]
 
Basile VS, Masellis M, McIntyre RS, et al: Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 62 (suppl 23):45–66, 2001
 
Bell R, McLaren A, Galanos J, et al: The clinical use of plasma clozapine levels. Aust N Z J Psychiatry 32:567–574, 1998
[PubMed]
 
Bitter I, Dossenbach MR, Brook S, et al: Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:173–180, 2004
[PubMed]
 
Bondolfi G, Dufour H, Patris M, et al: Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 155:499–504, 1998
[PubMed]
 
Braff DL, Swerdlow NR, Geyer MA: Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am J Psychiatry 156:596–602, 1999
[PubMed]
 
Breier AF, Malhotra AK, Su TP, et al: Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 156:294–298, 1999
[PubMed]
 
Breier A, Buchanan R, Irish D, et al: Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns, 1993. Psychiatr Serv 51:1249–1253, 2000
[PubMed]
 
Bromel T, Blum WF, Ziegler A, et al: Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 3:76–80, 1998
[PubMed]
 
Brunette MF, Drake RE, Xie H, et al: Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 32:637–643, 2006
[PubMed]
 
Buur-Rasmussen B, Brosen K: Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur Neuropsychopharmacol 9:453–459, 1999
[PubMed]
 
Calabrese JR, Kimmel SE, Woyshville MJ, et al: Clozapine for treatment-refractory mania. Am J Psychiatry 153:759–764, 1996
[PubMed]
 
Calderon J, Rubin E, Sobota WL: Potential use of ipratropium bromide for the treatment of clozapine-induced hypersalivation: a preliminary report. Int Clin Psychopharmacol 15:49–52, 2000
[PubMed]
 
Canuso CM, Goldman MB: Clozapine restores water balance in schizophrenic patients with polydipsia-hyponatremia syndrome. J Neuropsychiatry Clin Neurosci 11:86–90, 1999
[PubMed]
 
Chakos M, Lieberman J, Hoffman E, et al: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 158:518–526, 2001
[PubMed]
 
Chengappa KN, Goldstein JM, Greenwood M, et al: A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther 25:530–541, 2003
[PubMed]
 
Chiodo LA, Bunney BS: Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3:1607–1619, 1983
[PubMed]
 
Citrome L, Volavka J, Czobor P, et al: Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 52:1510–1514, 2001
[PubMed]
 
Claghorn J, Honigfeld G, Abuzzahab FS Sr, et al: The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7:377–384, 1987
[PubMed]
 
de la Chapelle A, Kari C, Nurminem M, et al: Clozapine-induced agranulocytosis: a genetic and epidemiologic study. Hum Genet 37:183–194, 1977
 
Dettling M, Cascorbi I, Roots I, et al: Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-Jewish Caucasian sample. Arch Gen Psychiatry 58:93–94, 2001
[PubMed]
 
Diebold K, Michel G, Schweizer J, et al: Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders? Pharmacopsychiatry 31:60–67, 1998
[PubMed]
 
Drake RE, Xie H, McHugo GJ, et al: The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 26:441–449, 2000
[PubMed]
 
Drew L, Herdson P: Clozapine and constipation: a serious issue. Aust N Z J Psychiatry 31:149–150, 1997
[PubMed]
 
Dursun SM, Szemis A, Andrews H, et al: The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. J Psychiatry Neurosci 24:453–455, 1999
[PubMed]
 
Essock SM, Frisman LK, Covell NH, et al: Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch Gen Psychiatry 57:987–994, 2000
[PubMed]
 
Farde L, Nordstrom AL, Wiesel FA, et al: Positron emission tomographic analysis of central D and D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538–544, 1992
[PubMed]
 
Fischer-Cornelssen KA, Ferner UJ: An example of European multicenter trials: multispectral analysis of clozapine. Psychopharmacol Bull 12:34–39, 1976
[PubMed]
 
Fontaine KR, Heo M, Harrigan EP, et al: Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 101:277–288, 2001
[PubMed]
 
Frankenburg FR, Zanarini MC, Kando J, et al: Clozapine and body mass change. Biol Psychiatry 32:718–721, 1998
 
French Clozapine Parkinson Study Group: Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 353:2041–2042, 1999
 
Gaszner P, Makkos Z, Kosza P, et al: Agranulocytosis during clozapine therapy. Prog Neuropsychopharmacol Biol Psychiatry 26:603–607, 2002
[PubMed]
 
Gaulin BD, Markowitz JS, Caley CF, et al: Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 156:1270–1272, 1999
[PubMed]
 
Geyer MA, Krebs-Thomson K, et al: Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156(2–3):117–154, 2001
[PubMed]
 
Ghaeli P, Dufresne RL: Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 53:2079–2081, 1996
[PubMed]
 
Green AI, Tohen M, Patel JK, et al: Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 157:982–986, 2000
[PubMed]
 
Green AI, Burgess ES, Dawson R, et al: Alcohol and cannabis use in schizophrenia: effects of clozapine vs risperidone. Schizophr Res 60:81–85, 2003
[PubMed]
 
Green AI, Drake RE, Brunette MF, et al: Schizophrenia and co-occurring substance use disorder. Am J Psychiatry 164:402–408, 2007
[PubMed]
 
Griffith RW, Saamerli K: Clozapine and agranulocytosis. Lancet 2(7936):657, 1975
[PubMed]
 
Hayes G, Gibler B: Clozapine-induced constipation. Am J Psychiatry 152:298, 1995
[PubMed]
 
Heeringa M, Beurskens R, Schouten W, et al: Elevated plasma levels of clozapine after concomitant use of fluvoxamine. Pharm World Sci 21:243–244, 1999
[PubMed]
 
Helmchen H: Clinical experience with clozapine in Germany. Psychopharmacology (Berl) 99 (suppl):S80–S83, 1989
 
Henderson D: Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry 62 (suppl 23):39–44, 2001
 
Hippius H: A historical perspective of clozapine. J Clin Psychiatry 60 (suppl 12):22–23, 1999
 
Honigfeld G: Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv 47:52–56, 1996
[PubMed]
 
Honigfeld G, Patin J, Singer J: Clozapine: antipsychotic activity in treatment-resistant schizophrenics. Adv Ther 1:77–97, 1984
 
Honigfeld G, Arellano F, Sethi J, et al: Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 59 (suppl 3):3–7, 1998
 
Hummer M, Kurz M, Barnas C, et al: Clozapine-induced transient white blood count disorders. J Clin Psychiatry 55:429–432, 1994
[PubMed]
 
Jones KM, Stoukides CA: Clozapine in treatment of Parkinson's disease. Ann Pharmacother 26:1386–1377, 1992
[PubMed]
 
Joos AA, Konig F, Frank UG, et al: Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer. Pharmacopsychiatry 30:266–270, 1997
[PubMed]
 
Jungi WF, Fischer J, Senn HJ, et al: [Frequent cases of agranulocytosis due to clozapine (leponex) in eastern Switzerland.] Schweiz Med Wochenschr 107:1861–1864, 1977
[PubMed]
 
Kane J, Honigfeld G, Singer J, et al: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796, 1988
[PubMed]
 
Kane JM, Marder SR, Schooler NR, et al: Clozapine and haloperidol in moderately refractory schizophrenia. A 6-month randomized and double-blind comparison. Arch Gen Psychiatry 58:965–972, 2001
[PubMed]
 
Kapur S, Seeman P: Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry 158:360–369, 2001
[PubMed]
 
Killian JG, Kerr K, Lawrence C, et al: Myocarditis and cardiomyopathy associated with clozapine. Lancet 354(9193):1841–1845, 1999
 
Kingsbury SJ, Fayek M, Trufasiu D, et al: The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 62:347–349, 2001
[PubMed]
 
Klimke A, Klieser E: [The atypical neuroleptic clozapine (Leponex)—current knowledge and recent clinical aspects.] Fortschr Neurol Psychiatr 63:173–193, 1995
[PubMed]
 
Koller E, Schneider B, Bennett K, et al: Clozapine-associated diabetes. Am J Med 111:716–723, 2001
[PubMed]
 
Koponen HJ, Leinonen E, Lepola U: Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol 6:69–71, 1996
[PubMed]
 
Kraus T, Haack M, Schuld A, et al: Body weight and leptin plasma levels during treatment with antipsychotic drugs, patients with anorexia have low leptin levels. Am J Psychiatry 156:312–314, 1999
[PubMed]
 
Kronig MH, Munne RA, Szymanski S, et al: Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 152:179–182, 1995
[PubMed]
 
Kumari V, Soni W, Sharma T: Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiatry 156:1046–1051, 1999
[PubMed]
 
Kumra S, Frazier JA, Jacobsen LK, et al: Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 53:1090–1097, 1996
[PubMed]
 
Lamberti JS, Olson D, Crilly JF, et al: Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 163:1273–1276, 2006
[PubMed]
 
Lehman AF, Kreyenbuhl J, Buchanan RW, et al: The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 30:193–217, 2004a
 
Lehman AF, Lieberman JA, Dixon LB, et al: Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161 (2 suppl):1–56, 2004b
 
Levin TT, Barrett J, Mendelowitz A: Death from clozapine-induced constipation: case report and literature review. Psychosomatics 43:71–73, 2002
[PubMed]
 
Lewis SW, Barnes TR, Davies L, et al: Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 32:715–723, 2006
[PubMed]
 
Lieberman JA, Safferman AZ: Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q 63:51–70, 1992
[PubMed]
 
Lieberman JA, Yunis J, Egea E, et al: HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 47:945–948, 1990
[PubMed]
 
Macfarlane B, Davies S, Mannan K, et al: Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology 112:1707–1709, 1997
[PubMed]
 
Marder SR, Essock SM, Miller AL, et al: The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull 28:5–16, 2002
[PubMed]
 
Marder SR, Essock SM, Miller AL, et al: Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161:1334–1349, 2004
[PubMed]
 
McElroy SL, Dessain EC, Pope HG Jr, et al: Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 52:411–414, 1991
[PubMed]
 
McEvoy JP, Lieberman JA, Stroup TS, et al: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600–610, 2006
[PubMed]
 
Meged S, Stein D, Sitrota P, et al: Human leukocyte antigen typing, response to neuroleptics, and clozapine-induced agranulocytosis in Jewish Israeli schizophrenic patients. Int Clin Psychopharmacol 14:305–312, 1999
[PubMed]
 
Melkersson K, Hulting AL: [Antipsychotic drugs can affect hormone balance: weight gain, blood lipid disturbances and diabetes are important.] Lakartidningen 98:5462–5464, 5467–5469, 2001
 
Meltzer HY: Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. Curr Psychiatry Rep 4:279–283, 2002
[PubMed]
 
Meltzer HY, Okayli G: Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152:183–190, 1995
[PubMed]
 
Merrill DB, Goff DC: Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 25:32–41, 2005
[PubMed]
 
Meyer J, Loh C, Leckband SG, et al: Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract 12:5–10, 2006
[PubMed]
 
Miller AL, Hall CS, Buchanan RW, et al: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 65:500–508, 2004
[PubMed]
 
Miller DD: The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia. Ann Clin Psychiatry 8:99–109, 1996
[PubMed]
 
Miller DD, Fleming F, Holman TL, et al: Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 55 (suppl B):117–121, 1994
 
Miyasaki JM, Shannon K, Voon V, et al: Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:996–1002, 2006
[PubMed]
 
Muldoon MF, Manuck SB, Matthews KA: Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 301(6747):309–314, 1990
[PubMed]
 
Navarro V, Pons A, Romero A, et al: Topiramate for clozapine-induced seizures. Am J Psychiatry 158:968–969, 2001
[PubMed]
 
Newcomer JW: Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry 67(11):e16, 2006
 
Novartis: Clozaril (clozapine) tablets: prescribing information. Hanover, NJ, Novartis Pharmaceuticals, July 2002
 
Parkinson Study Group: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 340:757–763, 1999
 
Paton C, Whittington C, Barnes TR: Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol 27:198–204, 2007
[PubMed]
 
Pickar D, Owen RR, Litman RE, et al: Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry 49:345–353, 1992
[PubMed]
 
Pollak P, Tison F, Rascol O, et al: Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75:689–695, 2004
[PubMed]
 
Popli AP, Konicki PE, Jurjus GJ, et al: Clozapine and associated diabetes mellitus. J Clin Psychiatry 58:108–111, 1997
[PubMed]
 
Potkin SG, Bera R, Gulasekaram B, et al: Plasma clozapine concentrations predict clinical response in treatment resistant schizophrenia. J Clin Psychiatry 55 (9, suppl B):117–121, 1994
 
Raison CL, Guze BH, Kissell RL, et al: Successful treatment of clozapine-induced agranulocytosis with granulocyte colony-stimulating factor. J Clin Psychopharmacol 14:285–286, 1994
[PubMed]
 
Ranjan R, Meltzer HY: Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 40:253–258, 1996
[PubMed]
 
Reid WH, Mason M, Hogan T: Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr Serv 49:1029–1033, 1998
[PubMed]
 
Rosenheck R, Cramer J, Xu W, et al: A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 337:809–815, 1997
[PubMed]
 
Rothschild AJ: Management of psychotic, treatment-resistant depression. Psychiatr Clin North Am 19:237–252, 1996
[PubMed]
 
Safferman AZ, Lieberman JA, Alvir JM, et al: Rechallenge in clozapine-induced agranulocytosis (letter). Lancet 339(8804):1296–1297, 1992
[PubMed]
 
Sasaki N, Iwase M, Uchizono Y, et al: The atypical antipsychotic clozapine impairs insulin secretion by inhibiting glucose metabolism and distal steps in rat pancreatic islets. Diabetologia 49:2930–2938, 2006
[PubMed]
 
Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27–38, 2002
[PubMed]
 
Sernyak MJ, Leslie DL, Alarcon RD, et al: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159:561–566, 2002
[PubMed]
 
Shaw P, Sporn A, Gogtay N, et al: Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 63:721–730, 2006
[PubMed]
 
Shopsin B, Klein H, Aaronsom M, et al: Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison. Arch Gen Psychiatry 36:657–664, 1979
[PubMed]
 
Simpson GM, Cooper TA: Clozapine plasma levels and convulsions. Am J Psychiatry 135:99–100, 1978
[PubMed]
 
Simpson GM, Varga E: Clozapine—a new antipsychotic agent. Curr Ther Res Clin Exp 16:679–686, 1974
[PubMed]
 
Spina E, Avenoso A, Facciola G, et al: Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 13:141–145, 1998
[PubMed]
 
Spivak B, Roitman S, Vered Y, et al: Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol 21:245–250, 1998
[PubMed]
 
Spivak B, Lamschtein C, Talmon Y, et al: The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin Neuropharmacol 22:98–101, 1999
[PubMed]
 
Stevens JR: Clozapine: the yin and yang of seizures and psychosis. Biol Psychiatry 37:425–426, 1995
[PubMed]
 
Stevens JR, Denney D, Szot P, et al: Kindling with clozapine: behavioral and molecular consequences. Epilepsy Res 26:295–304, 1996
[PubMed]
 
Stroup TS, Lieberman JA, McEvoy JP, et al: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163:611–622, 2006
[PubMed]
 
Suppes T, Webb A, Paul B, et al: Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 156:1164–1169, 1999
[PubMed]
 
Swerdlow NR, Geyer MA: Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacol Biochem Behav 44:741–744, 1993
[PubMed]
 
Swerdlow NR, Bakshi V, et al: Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacology (Berl) 140:75–80, 1998
[PubMed]
 
Theisen FM, Cichon S, Linden A, et al: Clozapine and weight gain. Am J Psychiatry 158:816, 2001a
 
Theisen F, Linden A, Geller F, et al: Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication. J Psychiatr Res 35:339–345, 2001b
 
Tollefson GD, Birkett MA, Kiesler GM, et al: Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 49:52–63, 2001
[PubMed]
 
Toth P, Frankenburg FR: Clozapine and seizures: a review. Can J Psychiatry 39:236–238, 1994
[PubMed]
 
Usiskin SI, Nicolson R, Lenane M, et al: Gabapentin prophylaxis of clozapine-induced seizures. Am J Psychiatry 157:482–483, 2000
[PubMed]
 
Vailleau JL, Jeanny B, Chomard P, et al: [Importance of determining clozapine plasma level in follow-up of schizophrenic patients.] Encephale 22:103–109, 1996
[PubMed]
 
Varty GB, Higgins GA: Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Psychopharmacology (Berl) 122:15–26, 1995
[PubMed]
 
Volavka J, Czobor P, Sheitman B, et al: Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 159:255–262, 2002
[PubMed]
 
Walker AM, Lanzall LL, Arellano F, et al: Mortality in current and former users of clozapine. Epidemiology 8:671–677, 1997
[PubMed]
 
Weide R, Koppler H, Heymanns J, et al: Successful treatment of clozapine induced agranulocytosis with granulocyte–colony-stimulating factor (G-CSF). Br J Haematol 80:557–559, 1992
[PubMed]
 
Welch J, Manschreck T, Redmond D: Clozapine-induced seizures and EEG changes. J Neuropsychiatry Clin Neurosci 6:250–256, 1994
[PubMed]
 
Wickramanayake PD, Scheid C, Josting A, et al: Use of granulocyte colony-stimulating factor (filgrastim) in the treatment of non-cytotoxic drug-induced agranulocytosis. Eur J Med Res 1:153–156, 1995
[PubMed]
 
Wirshing DA, Spellberg BJ, Erhart SM, et al: Novel antipsychotics and new onset diabetes. Biol Psychiatry 44:778–783, 1998
[PubMed]
 
Wirshing DA, Wirshing WC, Kysar L, et al: Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60:358–363, 1999
[PubMed]
 
Wirshing DA, Boyd J, Meng LR: The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63:856–865, 2002a
 
Wirshing DA, Pierre JM, Marder SR, et al: Sexual side effects of novel antipsychotic medications. Schizophr Res 56:25–30, 2002b
 
Wirshing DA, Pierre JM, Wirshing WC: Sleep apnea associated with antipsychotic-induced obesity. J Clin Psychiatry 63:369–370, 2002c
 
Wirshing W, Ames D, Bisheff S, et al: Hepatic encephalopathy associated with combined clozapine and divalproex sodium treatment. J Clin Psychopharmacol 17:120–121, 1997
[PubMed]
 
Wolters EC, Berendse HW: Management of psychosis in Parkinson's disease. Curr Opin Neurol 14:499–504, 2001
[PubMed]
 
Wooltorton E: Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity. CMAJ 166:1185–1186, 2002
[PubMed]
 
Worm K, Kringsholm B, Steentoft A: Clozapine cases with fatal, toxic or therapeutic concentrations. Int J Legal Med 106:115–118, 1993
[PubMed]
 
Yazici KM, Erbas T, Yazici AH, et al: The effect of clozapine on glucose metabolism. Exp Clin Endocrinol Diabetes 106:475–477, 1998
[PubMed]
 
+

CME Activity

Add a subscription to complete this activity and earn CME credit.
Sample questions:
1.
Which of the following, when combined with clozapine, will dramatically increase clozapine plasma levels?
2.
Characteristics theorized to account for clozapine’s potent antipsychotic properties and its low propensity to produce extrapyramidal side effects (EPS) include all of the following except
3.
Most clinical guidelines for the treatment of schizophrenia recommend the use of clozapine in which of the following circumstances?
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 4.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 20.  >
Helping Parents, Youth, and Teachers Understand Medications for Behavioral and Emotional Problems: A Resource Book of Medication Information Handouts, 3rd Edition > Chapter 15.  >
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 49.  >
Topic Collections
Psychiatric News
PubMed Articles
Second-Generation Antipsychotics and Extrapyramidal Adverse Effects. Biomed Res Int 2014;2014():656370.doi:10.1155/2014/656370.
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation